Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 10/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.34 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22462034 | 1.00 | AOC2 (0.36) | AOC2MAOBNPC1RAB9AAOC3 | |
| SCHEMBL30321077 | 0.87 | L3MBTL1 (0.39) | AOC2MAOBAOC3SCN9A | |
| SCHEMBL21042102 | 0.87 | L3MBTL1 (0.39) | AOC2MAOBAOC3SCN9A | |
| SCHEMBL30527037 | 0.87 | L3MBTL1 (0.39) | AOC2MAOBAOC3SCN9A | |
| SCHEMBL22462047 | 0.84 | AOC2 (0.49) | AOC2MAOBAOC3 | |
| SCHEMBL30527072 | 0.84 | AOC2 (0.49) | AOC2MAOBAOC3 | |
| SCHEMBL21040306 | 0.84 | AOC2 (0.49) | AOC2MAOBAOC3 | |
| Hydrochloric Acid SCHEMBL22462192 | 0.83 | AOC2 (0.48) | AOC2MAOBAOC3 | |
| Hydrochloric Acid SCHEMBL22462191 | 0.83 | AOC2 (0.48) | AOC2MAOBAOC3 | |
| SCHEMBL15527151 | 0.75 | MAOB (0.52) | AOC2MAOBAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-03-11 | — | — | US | disclosed |
| EP-3715341-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2020-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | VAPB, VAPA, ADRA1D | AOC2 102/4885MAOB 1567/4885NPC1 133/4885 |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | VAPB, VAPA, ADRA1D | AOC2 102/4885MAOB 1567/4885NPC1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.